✦ LIBER ✦

Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with ‘low’ TMX and ‘high’ MAP doses

✍ Scribed by Carlo M. Camaggi; Elena Strocchi; Nadia Canova; Barbara Costanti; Franco Pannuti

Publisher: Springer
Year: 1985
Tongue: English
Weight: 270 KB
Volume: 14
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00258121

No coin nor oath required. For personal study only.

✦ Synopsis

Plasma levels of medroxyprogesterone acetate (MAP), tamoxifen (TMX) and its major metabolites, 4-hydroxy TMX and desmethyl TMX, were determined in five patients with advanced breast cancer following simultaneous MAP (2,000 mg/day) and TMX (20 mg/day) oral therapy. The interindividual variance in MAP plasma levels was wide; the mean plasma levels of both drugs were nearly identical, despite the large difference in the administered doses.

📜 SIMILAR VOLUMES

Medroxyprogesterone acetate (MAP) plasma

Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients

✍ Franco Pannuti; Carlo Maurizio Camaggi; Elena Strocchi; Michele Giovannini; Nadi 📂 Article 📅 1982 🏛 Springer 🌐 English ⚖ 141 KB

After simultaneous administration of medroxyprogesterone acetate (MAP) 1,000 mg PO and 1,000 mg IM to ten cancer patients, we observed mean plasma MAP profiles that could be exactly superimposed on the two absorption/decay curves obtained after administration of single doses IM or PO. Treatment with